1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
649E0DCF2C6ECA6CF652585220036CCE1
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-maximizing-impact-medical-affairs-oncology-product-launches-role-activities?OpenDocument
18
19OpenDocument
2044.222.131.239
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Launch Optimization

Maximizing the Impact of Medical Affairs in Oncology Product Launches: Role and Activities

ID: 5605


Features:

17 Info Graphics

15 Data Graphics

350+ Metrics


Pages/Slides: 42


Published: 2020


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Maximizing the Impact of Medical Affairs in Oncology Product Launches: Role and Activities”

STUDY OVERVIEW

The rapid pace of innovation in cancer treatments has raised the stakes for pharma companies preparing for new oncology product launches. And as an important conduit between pharma companies and key thought leaders, the Medical Affairs function oversees critical activities that span the periods of pre-launch, launch and post-launch.

Therefore, to maximize oncology launch impact, it is vital to clarify the emerging roles and activities that Medical Affairs is responsible for.

Best Practices, LLC conducted this benchmarking research to explore how Medical Affairs can maximize its oncology launch impact. This study provides insights and benchmarks around strategy planning, role, activities, cross-functional alignment and collaboration for an effective oncology launch.

KEY TOPICS
  • Medical Affairs role and activity effectiveness
  • Ensuring cross-functional alignment and collaboration
  • Adapting to ongoing changes in Medical Affairs landscape
  • Medical Affairs leading vs. supporting brand teams

KEY METRICS
  • How effective is your Medical Affairs organization in regard to listed activities for a successful launch?
  • What role does your Medical Affairs group play at launch in listed areas?
  • How does your Medical Affairs work with internal colleagues to ensure successful launch?
  • What is the role of your Medical Affairs group in cross-functional oncology launch teams?
  • What are the major pitfalls for Medical Affairs during oncology launch?

SAMPLE KEY FINDINGS
  • Medical Affairs can significantly boost its launch performance by improving brand team collaboration and alignment:
    • Improve brand team collaboration through team leadership structures, clear roles and responsibilities and by enabling activity ownership structures.
    • Improve brand team alignment by deploying work timelines and increasing strategy transparency to 24 months before the launch.
METHODOLOGY

Best Practices, LLC engaged over 35 oncology Medical Affairs experts from 25 pharmaceutical and biotechnology companies in this research study through a benchmarking survey, interviews and a roundtable discussion.


Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Chemical; Health Care; Diagnostic; Medical Device


Companies Profiled:
AbbVie; Alkermes; AstraZeneca; Boehringer Ingelheim; Celgene; Cipla; Clovis Oncology; Crescendo Bioscience; Curis; Daiichi Sankyo; Eisai; Exelixis ; GRAIL; Merck; Merck KGaA; Novartis; Roche; Sandoz; Sanofi Genzyme; Servier; Shire; Taiho Oncology; Takeda Pharmaceuticals; Torrent Pharmaceuticals Ltd.; Zydus Cadila

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.